Amgen Inc.
Company Snapshot
Company Overview
Amgen Inc. is a biotechnology firm that participates in the CKD space through its therapeutic offerings, with a primary focus on treating complications associated with advanced kidney disease, including anemia and mineral and bone disorders. Its involvement in nephrology focuses on biological and specialty pharmaceuticals used in clinical treatment, rather than dialysis services, renal equipment, or diagnostic solutions. It operates under a single reporting segment, human therapeutics, which encompasses its R&D, manufacturing, and global commercialization activities.
Amgen maintains an extensive international footprint supported by wholly owned subsidiaries and regional operations across North America, Europe, Asia-Pacific, and Latin America. With established operations in countries such as the United States, Germany, Switzerland, Japan, Canada, and Singapore, these entities facilitate local production, regulatory coordination, and market distribution, reinforcing Amgen’s presence in key global pharmaceutical markets.
Financial Highlights (FY 2025)
This information is available for BCC Research members only.
Amgen Inc. In News
Company's Business Segments
- Product sales : Prolia, ENBREL, Otezla, XGEVA, Repatha, Nplate, KYPROLIS, Aranesp, EVENITY, Vectibix, BLINCYTO, TEPEZZA, KRYSTEXXA and Other products
- Other revenues : Royalty income and corporate partner revenues.
Applications/End User Industries
- Production of White Blood Cells
- Chemotherapy
- Reducing the Risk of Infectio
- Treatment for Autoimmune Diseases
- Rheumatoid Arthritis
- Psoriasis
- Stimulate Red Blood Cell Production
- Anemia
- Chronic Kidney Disease
- Novel Therapies
- Academic Institutions
- CGD Specialist
- Aimovig
- Migraine
- Nephrology
- Oncology
- Melanoma
- Drug Development
- Healthcare Providers
- Pharmaceutical Distributors
- Diabetes
- Inflammatory disease
- Autoimmune Diseases
- Rare Disease